Essapeutics第二季度每股收益$（0.02）击败$（0.14）估计，销售额8238.5万美元，超过6314.2万美元估计

Esperion Therapeutics (NASDAQ: ESPR) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.14) by 85.51 percent. This is a 93.94 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $82.385 million which beat the analyst consensus estimate of $63.142 million by 30.48 percent. This is a 11.58 percent increase over sales of $73.834 million the same period last year.